Haematologica (Mar 2011)

IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach

  • Polina Stepensky,
  • Michael Weintraub,
  • Asaf Yanir,
  • Shoshana Revel-Vilk,
  • Frank Krux,
  • Kirsten Huck,
  • Rene M. Linka,
  • Avraham Shaag,
  • Orly Elpeleg,
  • Arndt Borkhardt,
  • Igor B. Resnick

DOI
https://doi.org/10.3324/haematol.2010.033910
Journal volume & issue
Vol. 96, no. 3

Abstract

Read online

Mutations in the IL-2-inducible T-cell kinase gene have recently been shown to cause an autosomal recessive fatal Epstein Barr virus (EBV) associated lymphoproliferation. We report 3 cases from a single family who presented with EBV-positive B-cell proliferation diagnosed as Hodgkin’s lymphoma. Single nucleotide polymorphism array-based genome-wide linkage analysis revealed IL-2-inducible T-cell kinase as a candidate gene for this disorder. All 3 patients harbored the same novel homozygous nonsense mutation C1764G which causes a premature stop-codon in the kinase domain. All cases were initially treated with chemotherapy. One patient remains in durable remission, the second patient subsequently developed severe hemophagocytic lymphohistiocytosis with multi-organ failure and died, and the third patient underwent a successful allogeneic bone marrow transplantation. IL-2-inducible T-cell kinase deficiency underlies a new primary immune deficiency which may account for part of the spectrum of Epstein Barr virus related lymphoproliferative disorders which can be successfully corrected by bone marrow transplantation.